Among patients with nonmetastatic, muscle-invasive bladder cancer (MIBC), treatment with neoadjuvant cisplatin-based combination chemotherapy (NAC) plus bladder-saving concurrent chemoradiation ...

Patients were randomly assigned to receive either neoadjuvant mitomycin C or no neoadjuvant therapy (control arm) prior to TURBT. In the experimental arm, patients underwent cystoscopy and tumor ...

Background: Interim results of the randomized phase II trial of neoadjuvant tislelizumab +/- oral APL-1202 (nitroxoline) revealed promising pathological complete response (pCR) rates and met ...

Meeting Coverage > GuCS Expert Video Roundtable Latest on Neoadjuvant Immunotherapy in Muscle-Invasive Bladder Cancer — Matthew Galsky, MD, leads a discussion with Guru Sonpavde, MD, and John ...

Bladder Preservation in Muscle-Invasive Bladder Cancer. ... [to neoadjuvant therapy]," study author Daniel Geynisman, MD, of Fox Chase Cancer Center in Philadelphia, told MedPage Today.

Among patients treated in the neoadjuvant setting, the 5-year cumulative incidence of bladder cancer death was 24% in the dd-MVAC arm and 38% in the GC arm (HR, 0.55; 95% CI, 0.39-0.78).

References: Imfinzi ® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer. News release. AstraZeneca. March 31, 2025 ...

In the neoadjuvant and adjuvant phases of arm C, pembrolizumab will be administered on day 1 and enfortumab vedotin will be administered on days 1 and 8 of each cycle. Enrollment is complete for arm A ...

Neoadjuvant chemotherapy followed by radical cystectomy is the standard treatment for cisplatin-eligible patients with muscle-invasive bladder cancer. Adding perioperative immunotherapy may ...

And, with 1063 participants, it is the largest study ever undertaken in muscle-invasive bladder cancer, noted Powles. The patient population had classic muscle-invasive disease (clinical tumor ...

Neoadjuvant chemotherapy (NACT) is a treatment for advanced ovarian cancer – cancer at stage III or IV.It uses chemo drugs to shrink tumors before any surgery is done to remove them. NACT uses a ...

Surgery was performed in 84% (LARCT-US) and 85% (AdmL) of patients, with an R0/R1 resection rate of 98%. Over a follow-up period of 3.6 to 7.6 years, disease-related treatment failure occurred in ...